ADPT vs GRAL vs NTRA Stock Comparison

Adaptive Biotechnologies, Grail and Natera Prices as of Nov 13, 2026 Peers: Industry group
GRAL GRAIL, Inc.
$115.89 -17.0% 1M +39.3% 1Y
Market cap
$4.98B
P/E
–
Revenue (TTM)
$66.30M
Div. yield
–
Diagnostic Labs Healthcare
NTRA Natera, Inc.
$319.09 -19.2% 1M +59.0% 1Y
Market cap
$41.80B
P/E
–
Revenue (TTM)
$2.91B
Div. yield
–
Diagnostic Labs Healthcare
6 wins

Head to Head

7 decided of 12

Natera leads on 6 of the 12 questions below (Natera 6, Adaptive Biotechnologies 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionADPTGRALNTRALeader
Larger companyMarket capitalisation $4.50B $4.98B $41.80B NTRA
Cheaper on earningsLower P/E, profitable companies only -63.8x -12.3x -253.7x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — — — –
Faster revenue growthRevenue growth, trailing twelve months +17.9% +12.3% +37.4% NTRA
More profitableNet margin, trailing twelve months -23.7% -255.1% -5.7% NTRA
Better return on capitalReturn on invested capital — — -9.9% –
Less leveragedLower net debt / EBITDA — — 5.6x –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +105.4% +39.3% +59.0% ADPT
Better 5-year returnAnnualised price return, 5 years -2.6%/yr — +22.7%/yr NTRA
Less volatileAnnualised volatility, 1 year 67.6% 112.9% 52.1% NTRA
Higher overall scoreMean of the five percentile scores vs peers 42/100 38/100 52/100 NTRA

Percentile Scorecard

ADPTGRALNTRA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisADPTGRALNTRA
Valuation 12 #87 of 99 5 #94 of 99 13 #86 of 99
Growth 83 #16 of 89 42 #52 of 89 80 #19 of 89
Profitability 25 #69 of 92 6 #87 of 92 35 #60 of 92
Financial Health 70 #32 of 103 100 #1 of 103 85 #16 of 103
Shareholder Returns 21 #50 of 63 – 45 #35 of 63
Overall 42 38 52
  • ADPT ranked among 103 companies in Healthcare Providers
  • GRAL ranked among 103 companies in Healthcare Providers
  • NTRA ranked among 103 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodADPTGRALNTRASPY
1 month +13.3%-17.0%-19.2% -2.0%
3 months +17.4%+70.8%+3.0% -2.8%
6 months +126.3%+94.3%+71.2% +2.0%
Year to date +78.8%+35.4%+39.3% +10.6%
1 year +105.4%+39.3%+59.0% +12.2%
3 years +610.0%—+512.2% +68.1%
3 years, per year +92.3%—+83.0% +18.9%
5 years -12.6%—+177.4% +61.4%
5 years, per year -2.6%—+22.7% +10.1%
10 years ——+2,761.8% +248.5%
10 years, per year ——+39.9% +13.3%

Risk

MeasureADPTGRALNTRASPY
Volatility, 1Y 67.6%112.9%52.1% 13.6%
Downside volatility, 1Y 62.9%129.8%53.1% 13.9%
Beta vs S&P 500, 1Y 1.572.901.29 1.00
Return / volatility, 1Y 1.560.351.13 0.90
Max drawdown, 5Y -92.8%-62.9%-75.7% -25.4%
From 52-week high -4.0%-27.1%-26.8% -3.2%
52-week high $30.26$158.92$436.00 $779.14
52-week low $12.41$43.03$182.65 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleADPTGRALNTRA
P/E now vs peer median -66.0xmedian 22.4x -13.3xmedian 22.4x -279.0xmedian 22.4x
P/S now vs peer median 15.7xmedian 1.3x 32.6xmedian 1.3x 15.8xmedian 1.3x
EV/EBITDA now vs peer median -132.7xmedian 14.2x -9.8xmedian 14.2x -248.1xmedian 14.2x
P/FCF now vs peer median -531.8xmedian 19.0x -16.6xmedian 19.0x 877.9xmedian 19.0x
P/B now vs peer median 25.5xmedian 2.6x 2.1xmedian 2.6x 24.6xmedian 2.6x
PEG now vs peer median -1.90median 0.84 —median 0.84 -7.78median 0.84

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsADPTGRALNTRA
Revenue $298.01M $66.30M $2.91B
Gross profit $220.98M $75.17M $1.84B
Operating income -$48.21M -$578.58M -$260.42M
Net income -$70.73M -$406.18M -$164.72M
Free cash flow -$8.82M -$312.00M $52.47M
R&D $83.18M $188.17M $856.40M
EPS (diluted) $-0.38 $-8.68 $-1.14
Cash & equivalents $75.62M $29.00M $1.10B
Total debt – – $80.30M
Shares (diluted) 186.88M 46.78M 144.07M
Enterprise value $3.41B $1.60B $37.42B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricADPTGRALNTRA
P/E -66.0x -13.3x -279.0x
P/FCF -531.8x -16.6x 877.9x
P/Operating cash flow -1,097x -16.9x 216.5x
P/S 15.7x 32.6x 15.8x
P/B 25.5x 2.1x 24.6x
P/Tangible book 25.6x 7.3x 30.4x
EV/EBITDA -132.7x -9.8x -248.1x
EV/EBIT -91.1x -7.6x -173.0x
EV/Revenue 14.7x 27.6x 15.5x
EV/FCF -498.0x -14.1x 858.4x
EV/Operating cash flow -1,027x -14.4x 211.7x
PEG (3Y EPS CAGR) -1.90 – -7.78

Growth

14 metrics
MetricADPTGRALNTRA
Revenue growth (1Y) 17.9% 12.3% 37.4%
Revenue CAGR (3Y) 18.4% – 43.3%
Gross profit growth (1Y) 21.7% 13.1% 41.1%
Gross profit CAGR (3Y) 27.3% – 68.2%
Operating income growth (1Y) 38.3% -0.7% 26.0%
Operating income CAGR (3Y) 37.3% – 19.7%
Net income growth (1Y) 11.1% 0.0% 46.7%
Net income CAGR (3Y) 28.8% – 30.9%
EPS growth (1Y) 22.7% 22.8% 49.3%
EPS CAGR (3Y) 34.7% – 35.9%
Operating cash flow growth (1Y) 92.9% 6.8% 9.5%
Operating cash flow CAGR (3Y) 70.1% – 40.7%
Free cash flow growth (1Y) 86.0% 5.4% -50.5%
Free cash flow CAGR (3Y) 62.8% – 29.4%

Profitability

14 metrics
MetricADPTGRALNTRA
Gross margin 74.2% 47.2% 63.3%
EBITDA margin -11.1% -282.4% -6.2%
Operating margin -16.2% -363.4% -9.0%
Pretax margin 5.1% -344.3% -7.7%
Net margin -23.7% -255.1% -5.7%
FCF margin -3.0% -196.0% 1.8%
Operating cash flow margin -1.4% -192.4% 7.3%
Return on equity -42.3% -16.3% -8.9%
Return on assets -10.7% -14.6% -6.1%
Return on invested capital – – -9.9%
Return on capital employed -8.6% -21.5% -12.5%
Asset turnover 0.5x 0.1x 1.1x
Cash conversion (OCF / net income) 0.1x 0.8x -1.3x
Stock comp / revenue 15.5% 40.3% 13.6%

Financial Health

11 metrics
MetricADPTGRALNTRA
Debt / assets – – 2.9%
Debt / equity – – 0.0x
Net debt / EBITDA – – 5.6x
Debt / FCF – – 1.5x
Liabilities / assets 73.1% 10.1% 32.0%
Equity / assets 26.9% 89.9% 68.0%
Interest coverage -5.3x – -70.8x
Current ratio 4.0x 8.9x 2.8x
Quick ratio 3.7x 8.6x 2.6x
Cash ratio 3.0x 8.4x 1.8x
Altman Z-score 3.45 5.53 31.15

Shareholder Returns

7 metrics
MetricADPTGRALNTRA
Dividend yield – – –
Net buyback yield -0.9% – -0.1%
Shareholder yield -0.9% – -0.1%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusADPTGRALNTRA
EPS, next fiscal year $-0.42FY2026 $-9.16FY2026 $-1.62FY2026
Revenue, next fiscal year $297.43MFY2026 $158.71MFY2026 $3.16BFY2026
Revenue growth, next FY +7.4%FY2026 +7.8%FY2026 +36.9%FY2026
Revenue growth, the year after +32.5% +37.5% +7.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersADPTGRALNTRA
Held by institutions 97.2% 85.4% 95.5%
Institutions holding 301 374 850
Change in shares held, QoQ +2.5% +8.4% +2.7%
Institutions buying 160 183 515
Institutions selling 87 101 240
Buyers to sellers 1.84 1.81 2.15

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ADPTGRALNTRA
ADPT 1.00 0.48 0.53
GRAL 0.48 1.00 0.43
NTRA 0.53 0.43 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ADPT, GRAL and NTRA?

Natera (NTRA) is the largest by market capitalisation: Adaptive Biotechnologies (ADPT) $4.50B, Grail (GRAL) $4.98B, Natera (NTRA) $41.80B.

Which company is growing faster?

Natera (NTRA) grew revenue fastest over the trailing twelve months: Adaptive Biotechnologies (ADPT) +17.9%, Grail (GRAL) +12.3%, Natera (NTRA) +37.4%.

Which company is more profitable?

Natera (NTRA) has the highest net margin (Adaptive Biotechnologies (ADPT) -23.7%, Grail (GRAL) -255.1%, Natera (NTRA) -5.7%).

Which stock has performed better?

Over the past year Adaptive Biotechnologies (ADPT) returned the most: Adaptive Biotechnologies (ADPT) +105.4%, Grail (GRAL) +39.3%, Natera (NTRA) +59.0%. Over five years, Natera (NTRA) compounded fastest (Adaptive Biotechnologies (ADPT) -2.6%/yr, Natera (NTRA) +22.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Natera (NTRA) has been the steadiest (Adaptive Biotechnologies (ADPT) 67.6%, Grail (GRAL) 112.9%, Natera (NTRA) 52.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ADPT, GRAL and NTRA?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Natera (NTRA) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.